Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher C Porter

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2016
Germ line mutations associated with leukemiasChristopher C Porter
Blood|July 1, 2008
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selectionChristopher C Porter, James DeGregori
Blood|June 29, 2019
ETV6-related thrombocytopenia and leukemia predispositionJorge Di Paola, Christopher C Porter
The Lancet. Oncology|February 2, 2013
Targeting developmental pathways in children with cancer: what price success?Lia Gore, James DeGregori, Christopher C Porter
Current Oncology Reports|August 16, 2019
Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial ImpactsSarah G Mitchell, Bojana Pencheva, Christopher C Porter
Pediatric Blood & Cancer|October 8, 2008
Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1XChristopher C Porter, Amy E Carver, Edythe A Albano
Leukemia Research|November 28, 2017
Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabineTamara B Garcia, Susan P Fosmire, Christopher C Porter
Plos Biology|March 9, 2010
Irradiation selects for p53-deficient hematopoietic progenitorsAndriy Marusyk, Christopher C Porter, Vadym Zaberezhnyy, et al.
Expert Review of Precision Medicine and Drug Development|October 10, 2019
The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?Kathleen E A Felton, Christopher C Porter, Jun J Yang
Oncotarget|July 30, 2015
ETV6 mutations define a new cancer predisposition syndromeGregory Kirkpatrick, Leila Noetzli, Jorg Di Paola, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Hematology. American Society of Hematology. Education Program|December 4, 2016
Germ line mutations associated with leukemiasChristopher C Porter
Blood|July 1, 2008
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selectionChristopher C Porter, James DeGregori
Blood|June 29, 2019
ETV6-related thrombocytopenia and leukemia predispositionJorge Di Paola, Christopher C Porter
The Lancet. Oncology|February 2, 2013
Targeting developmental pathways in children with cancer: what price success?Lia Gore, James DeGregori, Christopher C Porter
Current Oncology Reports|August 16, 2019
Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial ImpactsSarah G Mitchell, Bojana Pencheva, Christopher C Porter
Pediatric Blood & Cancer|October 8, 2008
Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1XChristopher C Porter, Amy E Carver, Edythe A Albano
Leukemia Research|November 28, 2017
Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabineTamara B Garcia, Susan P Fosmire, Christopher C Porter
Plos Biology|March 9, 2010
Irradiation selects for p53-deficient hematopoietic progenitorsAndriy Marusyk, Christopher C Porter, Vadym Zaberezhnyy, et al.
Expert Review of Precision Medicine and Drug Development|October 10, 2019
The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?Kathleen E A Felton, Christopher C Porter, Jun J Yang
Oncotarget|July 30, 2015
ETV6 mutations define a new cancer predisposition syndromeGregory Kirkpatrick, Leila Noetzli, Jorg Di Paola, et al.
Pageof 8